Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study
Top Cited Papers
- 30 March 2004
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 109 (12), 1509-1513
- https://doi.org/10.1161/01.cir.0000121736.16643.11
Abstract
Background— The AFFIRM Study showed that treatment of patients with atrial fibrillation and a high risk for stroke or death with a rhythm-control strategy offered no survival advantage over a rate-control strategy in an intention-to-treat analysis. This article reports an “on-treatment” analysis of the relationship of survival to cardiac rhythm and treatment as they changed over time.Keywords
This publication has 13 references indexed in Scilit:
- Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) StudyCirculation, 2004
- Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillationJournal of the American College of Cardiology, 2003
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial FibrillationNew England Journal of Medicine, 2002
- Baseline characteristics of patients with atrial fibrillation: The AFFIRM StudyAmerican Heart Journal, 2002
- Atrial Fibrillation Follow-Up Investigation of Rhythm Management—The AFFIRM Study DesignThe American Journal of Cardiology, 1997
- Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial FibrillationArchives of Internal Medicine, 1994
- Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillationJournal of the American College of Cardiology, 1992
- Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial InfarctionNew England Journal of Medicine, 1992
- Events in the cardiac arrhythmia suppression trial (CAST): Mortality in the entire population enrolledJournal of the American College of Cardiology, 1991
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991